Global Epilepsy Market 2014-2018

Global Epilepsy Market 2014-2018

Category : Pharmaceuticals
Published On : November  2014
Pages : 78



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com
About Epilepsy 
Epilepsy is defined as a spectrum of brain disorders varying from benign symptoms to severe, disabling, and life-threatening symptoms. It can be caused by various factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and birth trauma. However, when the underlying cause of the disease is unidentified, as occurs in majority of the cases, it is known as idiopathic epilepsy. Epilepsy is characterized by repeated occurrence of generalized or focal seizures. Seizures result from an imbalance between the inhibitory and excitatory signals of the brain leading to sudden-onset of excitation. The occurrence of two or more unprovoked seizures is an important criteria to diagnose a person with seizures as being epileptic. 
TechNavio's analysts forecast the Global Epilepsy market to grow at a CAGR of 5.06 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Epilepsy market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of anti-epileptic drugs approved for the treatment of symptoms of epilepsy. 
TechNavio's report, Global Epilepsy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Epilepsy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas 
• APAC        
• EMEA
Key Vendors
• GlaxoSmithKline
• Pfizer
• UCB
Other Prominent Vendors
• Abbvie
• Eisai
• F. Hoffmann-La Roche
• H. Lundbeck
• Janssen Pharmaceuticals
• Meda AB
• Novartis 
• Shire
• Sunovion Pharmaceuticals
• Supernus Pharmaceuticals
• Upsher-Smith Laboratories
• Valeant Pharmaceuticals International
Market Driver
• Unmet Medical Needs
• For a full, detailed list, view our report
Market Challenge
• Generic Erosion
• For a full, detailed list, view our report
Market Trend
• Reformulation of Marketed Drugs
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Generation of Drugs
08. Geographical Segmentation
08.1 Epilepsy Market in the Americas
08.1.1 Market Size and Forecast
08.2 Epilepsy Market in the EMEA Region
08.2.1 Market Size and Forecast
08.3 Epilepsy Market in the APAC Region
08.3.1 Market Size and Forecast
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
16.1 Competitive Scenario
16.1.1 Key News
16.1.2 Mergers and Acquisitions
16.2 Market Share Analysis 2013
16.2.1 Pfizer
16.2.2 UCB
16.2.3 GlaxoSmithKline
16.3 Other Prominent Vendors
17. Key Vendor Analysis
17.1 GlaxoSmithKline
17.1.1 Key Facts
17.1.2 Business Overview
17.1.3 Business Segmentation
17.1.4 Business Segmentation by Revenue 2012 and 2013
17.1.5 Sales by Geography
17.1.6 Pipeline Products
17.1.7 Business Strategy
17.1.8 Key Information
17.1.9 SWOT Analysis
17.2 Pfizer
17.2.1 Key Facts
17.2.2 Business Overview
17.2.3 Business Segmentation by Revenue 2013
17.2.4 Business Segmentation by Revenue 2012 and 2013
17.2.5 Geographical Segmentation by Revenue
17.2.6 Business Strategy
17.2.7 Key Developments
17.2.8 SWOT Analysis
17.3 UCB
18. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Epilepsy Market 2013-2018 (US$ million)
Exhibit 3: Global Epilepsy Market Segmentation by Generation of Drugs
Exhibit 4: Revenue and CAGR of Major Epilepsy Markets 2013 (US$ million)
Exhibit 5: Global Epilepsy Market by Geographical Segmentation 2013
Exhibit 6: Global Epilepsy Market by Geographical Segmentation 2018
Exhibit 7: Global Epilepsy Market by Geographical Segmentation 2013-2018 (US$ million)
Exhibit 8: Global Epilepsy Market by Geographical Segmentation 2013-2018
Exhibit 9: Epilepsy Market in the Americas 2013-2018
Exhibit 10: Epilepsy Market in the Americas by Geography 2013 (US$ million)
Exhibit 11: Epilepsy Market in North America 2013-2018
Exhibit 12: Epilepsy Market in the US 2013-2018
Exhibit 13: Epilepsy Market in Canada 2013-2018
Exhibit 14: Epilepsy Market in EMEA by Geography 2013
Exhibit 15: Epilepsy Market in EMEA 2013-2018
Exhibit 16: Epilepsy Market in Europe 2013-2018
Exhibit 17: Epilepsy Market in APAC by Geography 2013
Exhibit 18: Revenue and CAGR of Epilepsy Market in APAC by Geography 2013 (US$ million)
Exhibit 19: Epilepsy Market in APAC 2013-2018
Exhibit 20: Epilepsy Market in Japan 2013-2018
Exhibit 21: Epilepsy Market in Australia 2013-2018
Exhibit 22: Epilepsy Market in China 2013-2018
Exhibit 23: Epilepsy Market in India 2013-2018
Exhibit 24: Impact of loss of exclusivity in Canadian market for Lyrica
Exhibit 25: Lyrica Revenue 2011-2013 (US$ million)
Exhibit 26: Neurontin Revenue 2011-2013 (US$ million)
Exhibit 27: Vimpat Revenue 2011-2013 (US$ million)
Exhibit 28: Vimpat Sales by Geographical Segmentation 2013
Exhibit 29: Keppra/Keppra XR Revenue 2011-2013 (US$ million)
Exhibit 30: Keppra/Keppra XR Sales by Geographical Segmentation 2013
Exhibit 31: Lamictal Revenue 2011-2013 (US$ million)
Exhibit 32: Lamictal Sales by Geographical Segmentation 2013
Exhibit 33: GlaxoSmithKline: Business Segmentation 2013
Exhibit 34: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 35: GlaxoSmithKline: Sales by Geography 2013
Exhibit 36: GlaxoSmithKline: Pipeline Products 2013
Exhibit 37: Pfizer: Business Segmentation by Revenue 2013
Exhibit 38: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 39: Pfizer: Geographical Segmentation by Revenue 2013



Enquiry Before Buy
image
Can´t read the image ? refresh here.